Alzheimer's Disease

Companies Alzheimer's Disease

SunRegen Healthcare AG, Switzerland

SunRegen Healthcare AG is a pioneering biopharmaceutical company based in Basel Area of Switzerland. Our mission is to develop novel drugs inspired by traditional medicine to treat neurodegenerative diseases. Our team is composed of passionate, innovative and persistent founders who have track recor more

Asceneuron SA, Switzerland

Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. more

Alzheon, Inc., USA

We are a clinical-stage biopharmaceutical company with a Phase 3-ready program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders. We are developing these disease modifying treatments by leveraging our expertise in inhibiting protein m more

News Alzheimer's Disease

• Alzheimer’s: Protective Immune Cells Active Decades Before Symptom Onset
  

  In individuals with a genetic predisposition to Alzheimer’s disease, the immune cells of the brain – the “microglia” – start exerting a protective effect up to two decades before the first symptoms appear. A team from Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) and Ludwig-Maximilians more

• Researchers find a ‘vicious cycle’ between excessive daytime napping and Alzheimer’s dementia
  

  Daytime napping is common among older adults. The longitudinal relationship between daytime napping and cognitive aging, however, is unknown. A new cohort study by investigators from Brigham and Women’s Hospital found a bidirectional link between the two: excessive daytime napping predicted an incre more

• Could leaky blood vessels in the brain be a culprit in Alzheimer’s disease?
  

  Alzheimer’s disease is an enormous problem that, with an aging population, will only get bigger. More than 6 million Americans are living with Alzheimer’s disease, and 1 in 3 seniors will die of it, according to the Alzheimer’s Association. By 2050, the cost of Alzheimer’s disease, currently estimat more

Videos Alzheimer's Disease

Chaperones - folding helpers in the cell

Nothing works without the correct form: For most proteins, there are millions of ways in which these molecules, composed of long chains of amino acids, can be folded - but only one way is the right one. Researchers in the department "Cellular Biochemistry" at the Max Planck Institute for Biochem ... more

White papers Alzheimer's Disease

• Novel aggregation-specific fluorogen monitors prefibrillar protein aggregation by fluorescence polarisation (FP)
  

  Highly ordered protein aggregates, termed amyloid fibrils, are associated with a broad range of diseases, many of which are neurodegenerative more

Publications Alzheimer's Disease

• On the role of sidechain size and charge in the aggregation of A{beta}42 with familial mutations [Biophysics and Computational Biology]

  The aggregation of the amyloid-β (Aβ) peptide into amyloid fibrils is associated with Alzheimer’s disease, and several point mutations leading to early-onset disease have been identified in Aβ. By studying the aggregation of five disease-related mutations in vitro, we rationalize their link to famil more

• Lipidated apolipoprotein E4 structure and its receptor binding mechanism determined by a combined cross-linking coupled to mass spectrometry and molecular dynamics approach

  by Nicolas Henry, Eva-Maria Krammer, Florian Stengel, Quentin Adams, François Van Liefferinge, Ellen Hubin, Rui Chaves, Rouslan Efremov, Ruedi Aebersold, Guy Vandenbussche, Martine Prévost, Vincent Raussens, Stéphanie Deroo Apolipoprotein E (apoE) is a forefront actor in the transport of lipids a more

• Near-atomic model of microtubule-tau interactions

  Tau is a developmentally regulated axonal protein that stabilizes and bundles microtubules (MTs). Its hyperphosphorylation is thought to cause detachment from MTs and subsequent aggregation into fibrils implicated in Alzheimer’s disease. It is unclear which tau residues are crucial for tau-MT inter more